These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21692668)

  • 1. The rise of antimicrobial resistance: a clear and present danger.
    Holmes NE; Howden BP
    Expert Rev Anti Infect Ther; 2011 Jun; 9(6):645-8. PubMed ID: 21692668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with recovery of multidrug-resistant bacteria in a combat support hospital in Iraq.
    Aldous WK; Co EM
    Infect Control Hosp Epidemiol; 2010 Apr; 31(4):425-7. PubMed ID: 20184421
    [No Abstract]   [Full Text] [Related]  

  • 3. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there any rationale for treatment of Staphylococcus aureus infections with antimicrobials that are determined to be ineffective in vitro?
    Uekötter A; Peters G; Becker K
    Clin Microbiol Infect; 2011 Aug; 17(8):1142-7. PubMed ID: 21672081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
    Bouchillon SK; Iredell JR; Barkham T; Lee K; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Moet GJ; Jones RN; Biedenbach DJ; Stilwell MG; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):7-13. PubMed ID: 17059876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of topical antimicrobial agents against multidrug-resistant bacteria recovered from burn patients.
    Glasser JS; Guymon CH; Mende K; Wolf SE; Hospenthal DR; Murray CK
    Burns; 2010 Dec; 36(8):1172-84. PubMed ID: 20542641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial resistance in Europe and its potential impact on empirical therapy.
    Rossolini GM; Mantengoli E
    Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():2-8. PubMed ID: 19040461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial.
    Rodloff AC; Leclercq R; Debbia EA; Cantón R; Oppenheim BA; Dowzicky MJ
    Clin Microbiol Infect; 2008 Apr; 14(4):307-14. PubMed ID: 18261126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging resistance in Gram-negative pathogens and implications for clinical practice.
    Cantón R; Lumb J
    Future Microbiol; 2011 Jan; 6(1):19-22. PubMed ID: 21162632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus.
    Deresinski S
    J Infect Dis; 2009 Mar; 199(5):605-9. PubMed ID: 19199551
    [No Abstract]   [Full Text] [Related]  

  • 13. Evolving problems with resistant pathogens.
    Chastre J
    Clin Microbiol Infect; 2008 Apr; 14 Suppl 3():3-14. PubMed ID: 18318874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diabetic foot infections. Prevalence and antibiotic sensitivity of the causative microorganisms].
    Martínez-Gómez Dde A; Ramírez-Almagro C; Campillo-Soto A; Morales-Cuenca G; Pagán-Ortiz J; Aguayo-Albasini JL
    Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):317-21. PubMed ID: 19237227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).
    Biedenbach DJ; Moet GJ; Jones RN
    Diagn Microbiol Infect Dis; 2004 Sep; 50(1):59-69. PubMed ID: 15380279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tigecycline resistance in Australian antibiotic-resistant Gram-negative bacteria.
    Iredell J; Thomas L; Power D; Mendes E
    J Antimicrob Chemother; 2007 Apr; 59(4):816-8. PubMed ID: 17353224
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimising outcomes of hospital infections through appropriate empirical antimicrobial therapy. Introduction.
    Lode H
    Clin Microbiol Infect; 2008 Apr; 14 Suppl 3():1-2. PubMed ID: 18318873
    [No Abstract]   [Full Text] [Related]  

  • 19. [Antimicrobial susceptibility of methicillin-resistant Staphylococcus aureus strains from outpatient individuals].
    García-Agudo L; Huertas M; Asencio MÁ; Carranza R; García-Martos P
    Rev Esp Quimioter; 2011 Jun; 24(2):91-5. PubMed ID: 21667001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.
    Bouchillon SK; Hoban DJ; Johnson BM; Stevens TM; Dowzicky MJ; Wu DH; Bradford PA
    Diagn Microbiol Infect Dis; 2005 Apr; 51(4):291-5. PubMed ID: 15808321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.